Safety and efficacy of adding topical clobetasol propionate to etanercept in patients with moderate to severe plaque psoriasis - 13/02/13
Doi : 10.1016/j.jaad.2012.12.870
Le texte complet de cet article est disponible en PDF.
Mark G. Lebwohl, MD, Mount Sinai Medical Center, New York, NY, United States; David Pariser, MD, Virginia Clinical Research, Inc, Norfolk, VA, United States; Gregory Kricorian, MD, Amgen Inc, Thousand Oaks, CA, United States; John Koo, MD, University of California at San Francisco, San Francisco, CA, United States; Kristina Callis Duffin, MD, University of Utah, Health Sciences Center, Salt Lake City, UT, United States; Leon Kircik, MD, Derm Research, PLLC, Louisville, KY, United States
Le texte complet de cet article est disponible en PDF.| Study sponsored by Immunex Corporation, a wholly owned subsidiary of Amgen Inc and by Wyeth, which was acquired by Pfizer. |
© 2013
Publié par Elsevier Masson SAS.
Vol 68 - N° 4S1
P. AB211 - avril 2013 Retour au numéro
Article précédent
- Safe and effective approach of 4 immune-mediated inflammatory diseases with 1 biologic: Our results
- Screening for metabolic syndrome in psoriasis patients: Hurdles and solutions in a tertiary dermatologic hospital in Singapore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?